Hong Kong—17 June 2026—Brii Biosciences Limited has activated a share buy-back programme of up to HK$60.00 million, utilising the 10% general mandate approved by shareholders on 16 June 2026.

The initiative authorises on-market repurchases of no more than 10% of the company’s issued share capital (excluding any treasury shares) between the date of this announcement and the next annual general meeting slated for 2027. Repurchased shares may be cancelled or held as treasury stock, subject to prevailing market conditions and capital-management requirements.

Management stated that the prevailing share price does not reflect the company’s operating performance, asset value, or growth prospects. Existing cash resources will fund the buy-backs, and the board affirmed that the programme will be executed only when deemed in the best interests of both the company and its shareholders.

All transactions will comply with Brii Biosciences’ memorandum and articles of association, the Hong Kong Listing Rules—including the prohibition on repurchases during restricted periods under Rule 10.06(2)(e)—and other applicable regulations. The timing, quantity and pricing of any repurchase remain at the board’s absolute discretion.

Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares, as there is no assurance regarding the extent or execution of the buy-back programme.